Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Cancer With Peritoneal Carcinomatosis
Peritoneal carcinomatosis of recurrent endometrial cancer (EC) is a rare clinical entity with dismal prognosis. The purpose of this study was the presentation of the outcomes of patients with peritoneal carcinomatosis from recurrent endometrial cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The files of the patients with recurrent EC and peritoneal carcinomatosis treated with CRS and HIPEC between 2000 and 2024 were retrospectively reviewed. Clinical and histopathological variables were correlated to survival, morbidity, and mortality. CRS plus HIPEC was performed in 23 female patients, mean age 60.4±7.9 (48-75) years. The mean peritoneal cancer index was 10.6±6 (3-39). Complete or near-complete cytoreduction was possible in 82.6% of patients. The incidence of severe morbidity and hospital mortality was 8.68% and 0%, respectively. Recurrence was recorded in 47% of patients. The overall 5- and 10-year survival was 78%. The completeness of cytoreduction score was identified as the single possible prognostic variable of survival. Complete cytoreduction combined with HIPEC appears to offer significant survival benefit with low morbidity in patients with recurrent EC and peritoneal carcinomatosis.